Abstract:Background: Intrahepatic Cholangiocarcinoma (iCCA) is a highly malignant tumor with limited treatment options that contributes largely to cancer-related deaths worldwide. Compared with traditional transcriptomic analysis, single-cell RNA sequencing (scRNA-seq) is emerging as a more advanced and popular tool for the in-depth exploration of cellular diversity and molecular complexity. As a next-generation proteasome inhibitor, MLN2238 presents better pharmacodynamics, pharmacokinetics, and therapeutic responses in various cancers. However, its effects and mechanisms of action in iCCA remain unknown.Methods: iCCA tumor heterogeneity was determined based on 4,239 qualified scRNA-seq data from 10 iCCA samples. The potential biological roles of proteasome-related genes in iCCA were investigated using a pseudo-trajectory reconstruction. The effect of MLN2238 on iCCA cell proliferation was estimated using the CCK-8, EdU, and clone formation assays. Flow cytometry was used to examine the effect of added MLN2238 on cell cycle and apoptosis levels. Autophagic flux was detected using AdPlus-mCherry-GFP-LC3B cells. ROS levels and mitochondrial membrane potential were determined using DCFH-DA probing and JC-1 staining. JNK activation and mitochondrial apoptosis were observed using western blotting and immunofluorescence microscopy, respectively. Finally, we used a tumor-bearing mouse model to validate its efficacy in vivo for iCCA treatment.Results: Proteasome-related genes were dysregulated in iCCA progression and expressed at higher levels in tumor tissues. MLN2238 suppressed cell proliferation, blocked the cell cycle in the G2/M phase, promoted apoptosis, and induced cytoprotective autophagy in iCCA cells. Furthermore, MLN2238 increased ROS levels and activated the JNK signaling pathway. Inhibition of ROS and JNK activation by NAC and SP600125 significantly reversed MLN2238-induced apoptosis. MLN2238 also suppressed the growth of iCCA tumors in vivo.Conclusion: Proteasome-related genes play pivotal roles in iCCA development. MLN2238, as a proteasome inhibitor, induces apoptosis in iCCA cells through ROS/JNK/mitochondrial signaling pathways, and hence, making MLN2238 a potential therapeutic choice for iCCA.

Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway

Isoalantolactone exerts anti‐melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models

Isoalantolactone Induces Cell Cycle Arrest, Apoptosis and Autophagy in Colorectal Cancer Cells

Isoalantolactone Induces Reactive Oxygen Species Mediated Apoptosis In Pancreatic Carcinoma Panc-1 Cells

Anticancer potential of isoalantolactone in testicular cancer: an analysis of cytotoxicity, apoptosis, and signaling pathways

The Inhibitory Effect of 3Β-Hydroxy-12-oleanen-27-oic Acid on Growth and Motility of Human Hepatoma HepG2 Cells Through JNK and Akt Signaling Pathway

Isoalantolactone inhibits the proliferation of human liver cancer cells by inducing intrinsic apoptosis

Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells.

ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma Via Downregulation of PI3K/AKT/mTOR Pathway in Vivo and in Vitro

Isoalantolactone Increases the Sensitivity of Prostate Cancer Cells to Cisplatin Treatment by Inducing Oxidative Stress

Alantolactone Exhibits Antiproliferative and Apoptosis-Promoting Properties in Colon Cancer Model Via Activation of the MAPK-JNK/c-Jun Signaling Pathway

Ethyl Acetate Extract from Inulaï¿½helenium L. Inhibits the Proliferation of Pancreatic Cancer Cells by Regulating the STAT3/AKT Pathway

Alantolactone Induces Apoptosis and Improves Chemosensitivity of Pancreatic Cancer Cells by Impairment of Autophagy-Lysosome Pathway Via Targeting TFEB

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Growth Inhibition Effects of Isoalantolactone on K562/A02 Cells: Caspase-Dependent Apoptotic Pathways, S Phase Arrest, and Downregulation of Bcr/Abl

Alantolactone Induces Apoptosis Through ROS-mediated AKT Pathway and Inhibition of PINK1-mediated Mitophagy in Human HepG2 Cells.

Isoalantolactone Induces Intrinsic Apoptosis Through P53 Signaling Pathway in Human Lung Squamous Carcinoma Cells.

Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway

Isoalantolactone Inhibits Esophageal Squamous Cell Carcinoma Growth Through Downregulation of MicroRNA-21 and Derepression of PDCD4

Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway.

Isoalantolactone Inhibits the Migration and Invasion of Human Breast Cancer MDA-MB-231 Cells Via Suppression of the P38 MAPK/NF-κB Signaling Pathway.